Glioma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
In contrast, IDH1 wt expression is upregulated in all glioma grades (concentration >0.1) compared to control brain tissue (0.007 ± 0.0016).
|
30943868 |
2019 |
Glioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
IDH Inhibitors Target Common Glioma Mutation.
|
31217295 |
2019 |
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We hypothesize that the primary cell pool isolated from LGG tumor contains a heterogeneous population consisting tumor cells at various stages of tumor progression including cells with early genetic lesions if any prior to acquisition of IDH1 mutation.
|
30460631 |
2019 |
Glioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Therefore, MET uptake for glioma grading was more consistent for IDH1-wildtype tumours than for IDH1-mutant tumours.
|
31102001 |
2019 |
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
This theory also provides an explanation for some of the most perplexing observations, including the scarcity of proper model systems and the prevalence of IDH1 mutation in glioma.
|
31504231 |
2019 |
Glioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
T1+Gad performed best for IDH typing of glioblastoma (sensitivity 91.9%, specificity 100%, AUC 0.945) and ADC for non-Gadolinium-enhancing gliomas (sensitivity 85.7%, specificity 78.4%, AUC 0.877).
|
30927935 |
2019 |
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
All those results support the translational potential of strategies targeting gliomas carrying IDH1 mutations.
|
30857299 |
2019 |
Glioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Glioma grading can be differentiated and IDH1 mutational status can be predicted using IVIM.
|
31014573 |
2019 |
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
<sup>1</sup> H-MRS enables non-invasive detection of 2-hydroxyglutarate (2-HG), an oncometabolite accumulating in gliomas carrying mutations in the isocitrate dehydrogenase (IDH) genes.
|
30457203 |
2019 |
Glioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
<b>Results</b>: We found that PD-L2 expression level was significantly upregulated in higher grade glioma and IDH wild-type glioma.
|
30713802 |
2019 |
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In clinical samples of gliomas with IDH1 mutation, levels of D-2-hydroxyglutarate (D-2HG) were increased significantly compared with gliomas without IDH mutation.
|
31278288 |
2019 |
Glioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Development and Validation of an IDH1-Associated Immune Prognostic Signature for Diffuse Lower-Grade Glioma.
|
31824866 |
2019 |
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
IDH Mutation Analysis in Glioma Patients by CADMA Compared with SNaPshot Assay and two Immunohistochemical Methods.
|
29556922 |
2019 |
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Mutation of the isocitrate dehydrogenase (IDH) gene and co-deletion on chromosome 1p/19q is becoming increasingly relevant for the evaluation of clinical outcome in glioma.
|
30529899 |
2019 |
Glioma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Moreover, MEOX2 expression was associated with IDH1/2 wildtype molecular subtype and was significantly correlated with overall survival of all gliomas and, more interestingly, in lower grade glioma.
|
30659268 |
2019 |
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Arterial Spin Labeling for Glioma Grade Discrimination: Correlations with IDH1 Genotype and 1p/19q Status.
|
30878893 |
2019 |
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In 1 case, an IDH1 R132H-mutant glioma was misdiagnosed as a demyelinating condition by frozen section histology during the intraoperative consultation, and no resection was performed pending the final pathology report.
|
30611146 |
2019 |
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
IDH1/2 active site mutations confer a neomorphic enzyme activity producing the oncometabolite D-2-hydroxyglutarate (D-2HG), which generates the glioma CpG island methylation phenotype (G-CIMP).
|
31292202 |
2019 |
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers.
|
31222125 |
2019 |
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
MRI texture analysis could be used as a new noninvasive method for identification of gliomas with IDH1 mutation.
|
30777207 |
2019 |
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The mini-column method enables rapid identification of 2-HG, providing a promising strategy for intraoperative diagnosis of IDH1-mutated gliomas in the future.
|
30573870 |
2019 |
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
PI3K/mTOR inhibition of IDH1 mutant glioma leads to reduced 2HG production that is associated with increased survival.
|
31324855 |
2019 |
Glioma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
CD163 expression was up-regulated in IDH wild-type glioma and mesenchymal subtype.
|
31143523 |
2019 |
Glioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Novel IDH1-Targeted Glioma Therapies.
|
31768950 |
2019 |
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Our research provides valuable insights into the tissue metabolism of human IDH1 mutant glioma and unravels new lipid-related targets.
|
30596429 |
2019 |